STOCK TITAN

Veraxa Biotech (VRXA) Stock News

VRXA NASDAQ
Rhea-AI Summary

VERAXA Biotech (VRXA) presented its first animal proof-of-concept results for BiTAC-ADC cancer therapy technology at the World ADC Congress.

A single 3 mg/kg dose produced tumor regression in a breast cancer xenograft model, an animal model using transplanted tumors. A matched conventional antibody-drug conjugate, or ADC, performed similarly. No body-weight decrease was observed in the BiTAC-ADC treatment arm. Delivering only one component to the tumor produced no significant effect.

Additional laboratory studies showed discrimination between cancer and healthy cells and no active toxin release outside the tumor. Both components must reach the same cancer cell to activate toxicity. VERAXA sees potential for a second research and partnering pillar, while BiTAC-TCEs remain its priority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (VRXA) updated its implementation of FDA-aligned, human-relevant testing methods across preclinical programs for antibody-based cancer therapies.

These New Approach Methodologies, or NAMs, include cell-based assays and tissue models. VERAXA expects the shift to reduce development costs and timelines, potentially bypassing certain non-human primate toxicology studies. Initial BiTAC-TCE studies presented at AACR 2026 showed selective killing of cells bearing both targets, with better safety and matched efficacy versus a traditional T cell engager. New three-dimensional cell-model data showed consistent targeting specificity across cancer cell lines.

Testing also covered ten patient-derived lung cancer models. The panel used about ten mice, versus an estimated 200 or more for comparable live-animal efficacy studies. BiTAC induced T cell-mediated killing, while relevant controls showed minimal activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (VRXA) appointed Raju Willener as Chief Financial Officer, effective immediately, adding extensive global capital markets and corporate finance experience to its leadership team.

Willener has over three decades of international financial leadership across investment banking, asset management and corporate finance, including CFO, CIO, Country Head and Head of Corporate Finance roles in the U.S., Europe and Asia. Most recently, he served as CFO of Exentis Group after leading corporate development and M&A. VERAXA highlights his role in supporting capital strategy, strategic opportunity evaluation and advancement of its BiTAC®-based oncology pipeline of T cell engagers and bispecific ADCs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.03%
Tags
none
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals reported a research milestone in their alliance to develop antibody-oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro proof-of-concept work, an AOC candidate created by combining both companies’ technologies showed higher potency than the equivalent unconjugated, “naked” oligonucleotide.

According to VERAXA, this demonstrates that its click-chemistry-based conjugation platform can be efficiently applied beyond its core focus in solid tumors. Both parties are now discussing next steps to further advance this AOC collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) reported significant strengthening of its intellectual property in H1 2026, filing the first BiTAC-related patent applications covering composition of matter and its proprietary payload platform for BiTAC-TCE and BiTAC-ADC technologies and derived programs.

The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with additional auxiliary technology patents clearing opposition periods. Once newly filed applications are granted, VERAXA expects protection of its core technology suite, including click chemistry, conjugation, linker and payload innovations, through at least 2047.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) announced that bispecific antibody-drug conjugate program VXA-222, originating from its May 2025 alliance with OmniAb (NASDAQ: OABI), has achieved a key technical milestone and is advancing into the next collaboration phase as OmniAb’s discovery work has concluded.

VXA-222 is a bispecific ADC using an “AND-gate” design to target two antigens on solid tumors in a single molecule. VERAXA used OmniAb’s transgenic antibody discovery technologies, including OmniClic, to generate antibody leads and will now apply its proprietary linker and conjugation technology, and conduct in vitro and in vivo validation. VERAXA holds exclusive development and commercialization rights to products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue from such products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
partnership
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) reported that shareholders at its Extraordinary General Meeting on July 24, 2026 approved all Board proposals, with more than 99.94% of represented votes in favor. A total of 102,102,301 voting shares, equal to 72.20% of share capital, were represented.

The resolutions introduce conditional share capital for shareholder options and warrants, establish a capital band through December 31, 2030, and increase the maximum Board size from five to seven members. According to VERAXA, these changes are intended to enhance its corporate and financing flexibility to support acquisitions, strategic collaborations, capital markets activities, and continued investment in its BiTAC technology platform and oncology pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) has appointed Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately, succeeding Rick Austin, Ph.D., who will leave after a transition period. Erkel, previously Vice President of R&D at VERAXA, will lead development of the company’s proprietary BiTAC® bi-targeted tumor-associated cytotoxicity technology platforms to pursue safer, more effective therapies for solid tumors.

According to VERAXA, Erkel brings 20 years of antibody therapeutics experience spanning antibody engineering, discovery and preclinical development up to IND submission, including leadership roles at MorphoSys and Sloning BioTechnology. The company is advancing a pipeline of T cell engagers, bispecific ADCs and proprietary BiTAC formats toward clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.27%
Tags
none
-
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) reported that Germany’s Paul-Ehrlich-Institute (PEI) provided Scientific Advice on the biological rationale and non-clinical development plan for its lead BiTAC-TCE program. The feedback supports VERAXA’s dual-targeting, conditionally active BiTAC-TCE format and offers initial de-risking and greater clarity for its development strategy.

According to VERAXA, preclinical data presented at AACR 2026 showed the BiTAC-TCE candidate selectively attacked cancer cells expressing both targets, spared single-target cells, and achieved a superior safety profile with similar efficacy versus a traditional TCE, suggesting a potentially improved therapeutic index.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
Rhea-AI Summary

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with Ardigen, an AI-focused computational R&D partner, to support VERAXA’s expanding BiTAC® pipeline of T cell engagers (TCEs) and antibody drug conjugates (ADCs). The partnership aims to integrate Ardigen’s platform with VERAXA’s in-house AI to optimize dual cancer target selection for conditionally active therapies.

BiTAC-TCEs and planned BiTAC-ADCs employ a Boolean “AND-gate” logic, requiring co-expression of two targets on the same cancer cell for activation, which VERAXA believes may widen the therapeutic window and reduce on-target, off-tumor toxicity. Initial work will develop AI-enabled tools and models to identify synergistic cancer target pairs, leveraging large preclinical and clinical datasets, including programs that failed due to toxicity despite promising efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
partnership AI

FAQ

What is the current stock price of Veraxa Biotech (VRXA)?

Veraxa Biotech (VRXA) last closed at $1.04.

What is the market cap of Veraxa Biotech (VRXA)?

The market cap of Veraxa Biotech (VRXA) is approximately $147.1M.